Greater responsiveness to donepezil in alzheimer patients with higher levels of acetylcholinesterase based on attention task scores and a donepezil PET study

Alzheimer Disease and Associated Disorders

Volumn 26, Issue 2, 2012, Pages 113-118

  Kasuya, Masashi ^a   Meguro, Kenichi ^a   Okamura, Nobuyuki ^a   Funaki, Yoshihito ^b   Ishikawa, Hiroyasu ^a   Tanaka, Naofumi ^a   Iwata, Ren ^b   Yanai, Kazuhiko ^a  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b TOHOKU UNIVERSITY   (Japan)

Author keywords

Alzheimer disease; attention; donepezil; PET

Indexed keywords

ACETYLCHOLINESTERASE; DONEPEZIL;

AGED; ALZHEIMER DISEASE; ANTERIOR CINGULATE; ARTICLE; ATTENTION; BINDING SITE; BLOOD SAMPLING; CLINICAL GLOBAL IMPRESSION SCALE; COGNITION; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG PROTEIN BINDING; EXECUTIVE FUNCTION; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; NEUROIMAGING; NEUROLOGIC EXAMINATION; NEUROPSYCHOLOGY; POSITRON EMISSION TOMOGRAPHY; POSTERIOR CINGULATE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SCORING SYSTEM; TASK PERFORMANCE; TREATMENT DURATION; TREATMENT RESPONSE; WECHSLER INTELLIGENCE SCALE;

ACETYLCHOLINESTERASE; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; ATTENTION; CHOLINESTERASE INHIBITORS; FEMALE; HUMANS; INDANS; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PIPERIDINES; POSITRON-EMISSION TOMOGRAPHY;

EID: 84861457274     PISSN: 08930341     EISSN: None     Source Type: Journal    
DOI: 10.1097/WAD.0b013e3182222bc0     Document Type: Article

References (30)

1. Meguro K., Ishii H., Yamaguchi S., et al. Prevalence of dementia and dementing diseases in Japan: the Tajiri project. Arch Neurol. 2002;59:1109-1114. (Pubitemid 34755823)
2. Davies P., Maloney AJ. Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet. 1976;25:1403. (Pubitemid 8004505)
3. Shinotoh H., Namba H., Fukushi K., et al. Progressive loss of cortical acetylcholinesterase activity in association with cognitive decline in Alzheimer's disease: a positron emission tomography study. Ann Neurol. 2000;48:194-200. (Pubitemid 30617038)
4. Kadir A., Almkvist O., Wall A., et al. PET imaging of cortical 11C-nicotine binding correlates with the cognitive function of attention in Alzheimer's disease. Psychopharmacology. 2006; 188:509-520. (Pubitemid 46758966)
5. Darreh-Shori T., Meurling L., Pettersson T., et al. Changes in the activity and protein levels of CSF acetylcholinesterases in relation to cognitive function of patients with mild Alzheimer's disease following chronic donepezil treatment. J Neural Transm. 2006;113:1791-1801. (Pubitemid 44657676)
6. Figueiro M., Ilha J., Pochmann D., et al. Acetylcholinesterase inhibition in cognition-relevane brain areas of mice treated with a nootropic Amazonian herbal (Marapuama). Phytomedicine. 2010;17:956-962.
7. Birks J. Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst Rev. 2006;1:CD005593.
8. Winblad B., Engedal K., Soininen H., et al. A 1-year., randomized., placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology. 2001;57:489-495. (Pubitemid 32757598)
9. Homma A., Imai Y., Tago H., et al. Donepezil treatment of patients with severe Alzheimer's disease in a Japanese population: results from a 24-week., double-blind., placebocontrolled., randomized trial. Dement Geriatr Cogn Disord. 2008;25:399-407. (Pubitemid 351630073)
10. Folstein MF., Folstein SE., McHugh PR. "Mini-Mental State": a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189-198.
11. Rösler M., Anand R., Cicin-Sain A., et al. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomized controlled trial. BMJ. 1999;318:633-638.
12. Wilcock GK., Lilienfeld S., Gaens E. Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomized controlled trial. Galantamine International-1 Study Group. BMJ. 2000;321:1445-1449.
13. Kadir A., Darreh-Shori T., Almkvist O., et al. PET imaging of the in vivo brain acetylcholinesterase activity and nicotine binding in galantamine-treated patients with AD. Neurobiol Aging. 2008; 29:1204-1217. (Pubitemid 351822413)
14. Shiraishi T., Kikuchi T., Fukushi K., et al. Estimation of plasma IC50 of donepezil hydrochloride for brain acetylcholinesterase inhibition in monkey using N-[11C]methylpiperidin-4-yl acetate ([11C]MP4A) and PET. Neuropsychopharmacology. 2005; 30:2154-2161. (Pubitemid 41643966)
15. Shinotoh H., Aotsuka A., Fukushi K., et al. Effect of donepezil on brain acetylcholinesterase activity in patients with AD measured by PET. Neurology. 2001;56:408-410. (Pubitemid 32144159)
16. Bohnen NI., Kaufer DI., Hendrickson R., et al. Degree of inhibition of cortical acetylcholinesterase activity and cognitive effects by donepezil treatment in Alzheimer's disease. J Neurol Neurosurg Psychiatr. 2005;76:315-319. (Pubitemid 40299116)
17. Okamura N., Funaki Y., Tashiro M., et al. In vivo visualization of donepezil binding in the brain of patients with Alzheimer's disease. Br J Clin Pharmacol. 2008;65:472-479. (Pubitemid 351365133)
18. McKhann G., Drachman D., Folstein M., et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDSADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34:939-944. (Pubitemid 14076461)
19. US Department of Health Education and Welfare. Clinical Global Impression Scale (CGI): ECDEU Assessment Manual for Psychopharmacology. Rockville: US Department of Health Education and Welfare., National Institute of Mental Health; 1976:218-222.
20. Lezak MD., Howieson DB., Loring DW. Neuropsychological assessment. II. A Compendium of Tests and Assessment Techniques
21. Orientation and Attention 3rd ed. New York: Oxford University Press., 2004:368-369.
22. Sá nchez-Cubillo I., Periáñ ez JA., Adrover-Roig D., et al. Construct validity of the Trail-Making Test: Role of taskswitching., working memory., inhibition/interference control., and visuomotor abilities. J Int Neuropsychol Soc. 2009;15: 438-450.
23. Funaki Y., Kato M., Iwata R., et al. Evaluation of the binding characteristics of [5-(11)C-methoxy] Donepezil in the rat brain for in vivo visualization of acetylcholinesterase. J Pharmacol Sci. 2003;91:105-112. (Pubitemid 36575561)
24. Logan J. Graphical analysis of PET data applied to reversible and irreversible tracers. Nucl Med Biol. 2000;27:661-670.
25. Yasui-Furukori N., Furuya R., Takahata T., et al. Determination of donepezil., an acetylcholinesterase inhibitor., in human plasma by high-performance liquid chromatography with ultraviolet absorbance detection. J Chromatography. 2002;B768:261-265. (Pubitemid 34158861)
26. Tanaka Y., Hanyu H., Sakurai H., et al. Atrophy of the substantia innominata on magnetic resonance imaging predicts response to donepezil treatment in Alzheimer's disease patients. Dement Geriatr Cogn Disord. 2003;16:119-125. (Pubitemid 36736996)
27. Kaasinen V., Na? gren K., JärvenpääT., et al. Regional effects of donepezil and rivastigmine on cortical acetylcholinesterase activity in Alzheimer's disease. J Clin Psychopharmacol. 2002; 22:615-620. (Pubitemid 35416788)
28. Maelicke A., Samochocki M., Jostock R., et al. Allosteric sensitization of nicotinic receptors by galantamine., a new treatment strategy for Alzheimer's disease. Biol Psychiatr. 2001;49:279-288. (Pubitemid 32178437)
29. Hiraoka K., Okamura N., Funaki Y., et al. Quantitative analysis of donepezil binding to acetylcholinesterase using positron emission tomography and [5-(11)C-methoxy]donepezil. Neuroimage. 2009;46:616-623.
30. Ito H., Koyama M., Goto R., et al. Cerebral blood flow measurement with iodine-123-IMP SPECT., calibrated standard input function and venous blood sampling. J Nucl Med. 1995;36:2339-2342.